Iterum Therapeutics Public Limited Company, a clinical-stage pharmaceutical entity headquartered in Chicago, United States, has been making strides in the healthcare sector, particularly within the pharmaceutical industry. The company is dedicated to developing and marketing therapies aimed at addressing unmet medical needs, with a specific focus on anti-infectives for the treatment of multi-drug resistant pathogens. This focus positions Iterum Therapeutics as a key player in the global fight against antibiotic resistance, serving physicians and patients worldwide.

As of October 9, 2025, Iterum Therapeutics’ stock closed at $0.742 on the Nasdaq, where it is publicly traded. The company’s market capitalization stands at approximately $33,135,427 USD, reflecting its current valuation in the market. Over the past year, the stock has experienced significant volatility, with a 52-week high of $3.02 recorded on December 8, 2024, and a 52-week low of $0.611 on September 2, 2025. This fluctuation underscores the dynamic nature of the pharmaceutical industry and the challenges faced by companies in this sector.

Since its Initial Public Offering (IPO) on May 25, 2018, Iterum Therapeutics has been committed to advancing its pipeline of innovative therapies. The company’s strategic focus on anti-infectives is particularly pertinent given the increasing prevalence of multi-drug resistant infections, which pose a significant threat to global health. By targeting these resistant pathogens, Iterum Therapeutics aims to fill a critical gap in the current therapeutic landscape.

The company’s efforts are not only limited to the development of new drugs but also extend to ensuring that these therapies are accessible to a global audience. This commitment to serving physicians and patients worldwide is a cornerstone of Iterum Therapeutics’ mission. For those interested in learning more about the company’s initiatives and progress, additional information is available on their official website, www.iterumtx.com .

In summary, Iterum Therapeutics Public Limited Company continues to play a vital role in the pharmaceutical industry by focusing on the development of anti-infectives to combat multi-drug resistant pathogens. Despite the challenges reflected in its stock performance, the company remains dedicated to addressing critical unmet medical needs and contributing to global health solutions.